RBC Capital Raises NuVasive to Outperform (NUVA)
Shares of NuVasive traded down 0.15% during mid-day trading on Wednesday, hitting $20.34. NuVasive has a one year low of $11.02 and a one year high of $34.91. The company’s market cap is $878.2 million.
NuVasive last issued its quarterly earnings data on Monday, April 30th. The company reported $0.20 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.18 by $0.02. NuVasive’s revenue was up 21.8% compared to the same quarter last year. On average, analysts predict that NuVasive will post $0.24 earnings per share next quarter.
NUVA has been the subject of a number of other recent research reports. Analysts at Canaccord Genuity reiterated a “buy” rating on shares of NuVasive in a research note to investors on Tuesday, May 1st. Separately, analysts at Robert W. Baird upgraded shares of NuVasive from a “neutral” rating to an “outperform” rating in a research note to investors on Tuesday, May 1st. Finally, analysts at William Blair upgraded shares of NuVasive from a “market perform” rating to an “outperform” rating in a research note to investors on Tuesday, May 1st.
NuVasive, Inc. (NuVasive) is a medical device company. NuVasive focuses on developing minimally disruptive surgical products and procedures for the spine.